open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-14 11:19 (58 d 00:15 ago) – Posting: # 23752
Views: 1,248

How do open-label BE trials maintain blindness until the database is locked?
Holding a data review meeting before DBL to discuss whether PK parameters (such as Pre-dose concentration, Abnormal PK concentration profiles, λz estimation, %AUCextrap etc.) are included in the analysis set (without treatment assigment) will have risk of potential unblinding?

Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,823 posts in 4,786 threads, 1,633 registered users;
32 visitors (0 registered, 32 guests [including 7 identified bots]).
Forum time: 10:35 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz